MSH6 and cancer: Participants with pathogenic MLH1 variants had the highest rate of cancer at 40.9%, followed closely by those with pathogenic MSH6 variants at 40%, and those with pathogenic MSH2 variants at 28% (Table 2, “Personal cancer history”).